'VT-EBV-N' eligible for priority review and conditional marketing approval
ViGenCell's NK/T-cell lymphoma treatment candidate has been designated a fast-track advanced biopharmaceutical by South Korean regulators.
The company's VT-EBV-N is a new drug candidate being developed to treat EBV-positive extranodal NK/T-cell lymphoma, a rare and intractable blood cancer with a high recurrence rate. The EBV antigen-specific T-cell therapy was submitted for fast-track advanced biopharmaceutical designation in June.
The candidate was earlier designated a "rare drug under development" in 2019. In a Phase 2 trial, it achieved a disease-free survival rate of 95.0% — the primary endpoint — reaching statistical significance. The company said a 100% overall survival rate was maintained across the entire treatment group over a four-year follow-up period.
Fast-track advanced biopharmaceutical designation is granted only for treatments targeting life-threatening serious or rare diseases for which no alternative therapy exists. Designated products become eligible to apply for conditional marketing approval and receive tailored review by a dedicated assessment team as well as priority review benefits.
ViGenCell Chief Executive Ki Pyeong-seok said Tuesday the company would "prepare for conditional marketing approval without disruption by making full use of the expedited review process" and would also "accelerate discussions on global technology transfers."
freiheit@heraldcorp.com
